Over the past twelve months, interest in biotech penny stocks has continued to see new peaks. While this is partly due to the pandemic’s effects, it seems that it goes beyond this. Due to Covid, a massive influx of capital has come into the biotech industry. This is because of the entrance of retail investors with interest in finding the best penny stocks to buy for capitalizing on this trend.
One thing to keep in mind is that the heightened attention in these companies has also led to increased speculation. This speculation more often than not can mean higher volatility than usual. Now, this isn’t necessarily a bad thing, but it is something to keep in mind. With many penny stocks hitting new levels right now, it could be time to put a list together. With this in mind, here are four biotech penny stocks that have begun heating up this month.Hot Penny Stocks To Watch
- Vaccinex Inc. (NASDAQ: VCNX)
- Acasti Pharma Inc. (NASDAQ: ACST)
- AIM ImmunoTech Inc. (NYSE: AIM)
- Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)
One of the more interesting and albeit lesser-known biotech penny stocks is Vaccinex Inc. Vaccinex is working on many neurodegenerative diseases. Its leading drug candidate, known as pepinemab, could be a viable treatment for Huntington’s and Alzheimer’s diseases. Also, it could treat other neurodegenerative conditions.
The company states that its drug discovery platform ActivMAb, could help expand its pipeline in the long term. With several products being studied by the company, it looks like it could see an approved substance in the future. Also, the company could leverage its platforms to supply other biotech companies with the tools to produce novel drugs.
A few days ago, the company announced that it would be licensing its Anti-CCR8 antibody to Surface Oncology. Ernest Smith, Chief Scientific Officer at Vaccinex, stated that “we are thrilled to continue building on the recent success of our ActivMAb platform with the announcement of our licensing deal with Surface Oncology. We are pleased to have played a part in the development of this promising drug candidate and look forward to following continuing development of SRF114 and further interactions with Surface Oncology.”
In addition to this, the company has signed another big deal regarding its ActivMAb platform, which could prove beneficial in the coming future. These two deals have helped to push interest in VCNX.Acasti Pharma Inc.
ACST is a penny stock that investors have known about for quite some time. The popular biotech company has become a staple among many watch lists. Only two weeks ago, Acasti released its third-quarter 2021 fiscal results. Despite pulling in a net loss of around $3.2 million, this is more than $5 million less than the loss it took in the same quarter of the previous year.
At the end of the quarter, Acasti greatly improved its financial situation, with roughly $26.5 million in cash and cash equivalents. The company has worked heavily to research OM3 fatty acids and how they can aid those suffering from hypertriglyceridemia (HTG). It has been working on CaPre, which is a phospholipid therapeutic that utilizes OM3 as its base.
This recent financial update has helped to spark a new bullish rally for Acasti. While we do have to consider that HTG is for a specialized market, millions are suffering from it in the U.S. alone. However, in the meantime, Acasti is working hard to improve its pipeline. It is also looking for strategic alternatives to add more shareholder value in the market. Acasti engaged Oppenheimer & Co., Inc., as the company’s financial advisor to assist in the process. While no new updates have come about, yet, this has become a point of interest in the market.AIM ImmunoTech Inc.
AIM ImmunoTech is another biotech company gaining ground this week following Tuesday’s sell-off. The company has a large focus on cancer and immune deficiency disorder treatments. Its pipeline includes its Alferon N Injection product, which can be used as a treatment of certain STDs.
Also, the company produces Ampligen, which is in use for chronic fatigue syndrome. Recently, the company has been in studies for the potential of Ampligen to be used in the fight against Covid. While the goal is to use it as adjuvant therapy, the company is still in tests to see its efficacy. A few weeks ago, the company announced that it had received approval from the Ethics Committee in the Netherlands to begin a Phase I trial for Ampligen.
The goal is to see if it can be used in an intranasal setting, to see whether or not it can prevent or treat Covid-19. CEO Thomas Equals stated that “we are delighted and honored to receive Ethics Committee approval, an important step toward the initiation of the trial. We are on track for site initiation later this month and expect to begin enrolling participants in the study during the first quarter of 2021.”
Equels went on to state that “the Institute for Antiviral Research at Utah State University demonstrated that Ampligen was able to decrease SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dose concentrations.”
Because of this, the company has seen its role in the fight against Covid increase over time.Tonix Pharmaceuticals Holding Corp.
TNXP is another penny stock that we’ve covered quite a few times in the past several months. For some context, Tonix is a clinical-stage biopharmaceutical company working on the production of biologics. The company’s pipeline includes substances that treat both CNS disorders as well as immunology needs. The company has several compounds in various stages of approval, including its RELIEF Phase 3 trial. This trial should have results in Q2 2021.
Additionally, the company has a vaccine candidate known as TNX-1800. This could be a viable compound in the fight against Covid. It may take some time to see the finished results from this vaccine candidate, but in the meantime, the data is still highly encouraging. Recently, the company announced that it has agreed to license its oxytocin-based therapy to study its efficacy in treating a rare eating disorder. This license, which was given to two French research institutions, should help determine whether or not TNX-2900 can be used to treat Prader-Willi syndrome.
CEO of the company, Seth Lederman, stated that “Prader-Willi syndrome is a rare genetic disorder of failure to thrive in infancy and uncontrolled appetite and obesity in childhood and adulthood with no approved treatments available. With the license from Inserm Transfert, we have the opportunity to expand our ongoing efforts with intranasal potentiated oxytocin to this new indication.”
He states that the company will soon be submitting an Orphan Drug and Fast Track application to the FDA in the U.S. at the appropriate time. A few days earlier, the company closed on a $70 million stock offering.